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Therapeutic radiopharmaceuticals are drugs designed to destroy the cancer cell with ionizing radiation.
Unlike conventional chemotherapy and radiation therapy, therapeutic radiopharmaceutical destroys the
cancer cells selectively without damaging the normal tissue. These radiopharmaceuticals can be small
organic/inorganic molecules or they could be antibodies, peptides or hormones that have a radioisotope
attached to them. In this project a potential peptide based radiopharmaceutical was designed and
synthesized. This radiopharmaceutical involved a specially designed peptide Bombesin(7-14) that can
directly recognize various cancer cells (e.g., small lung, breast and prostate cancers). 105Rhodium (a
radioactive isotope of the element rhodium) was used as a radiation source due to its ideal nuclear and
chemical properties.  To attach the Rhodium-105 to the peptide, a chemical compound (acyclic
diaminodithioether) was used. In order to find the ideal ligand for Rhodium-105, several analogues of
acyclic diaminodithioether ligands were synthesized and their Rh(III) complexes were prepared and
analyzed. The coupling studies of the optimum acyclic diaminodithioether ligand to the Bombesin(7-14) was
accomplished. Finally, the attachment of the Rhodium-105 was performed to obtain the potential peptide
base radiopharmaceutical. 
